A Practical Guideline for MicroRNA Sequencing Data Analysis in Chronic Lymphocytic Leukemia

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2024 Dec 20

PMID 39702719

Authors

Tuulikki Suomela

Liang Zhang

Julio Vera

Heiko Bruns

Xin Lai

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. They have been associated with several diseases and cancers, including chronic lymphocytic leukemia (CLL). CLL is the most common form of adult leukemia, and its pathogenesis is driven by the deletion of miRNAs, such as the miR-15a/16-1 cluster. In addition to initiating the development of CLL, the function of miRNAs in regulating the progression of this tumor remains to be investigated. Here, we present a computational pipeline, from the processing of miRNA sequencing files to functional analysis, including differential gene expression and gene set enrichment analysis.We exemplified the utility of the pipeline by applying it to genome-wide small RNA sequencing data from a cohort of CLL patients. The analysis revealed dysregulated expression profiles of miRNAs in CLL. The target genes of these miRNAs are not only associated with the response of CLL patients to current therapies but also involved in several cancer hallmarks, including the avoidance of cell death, the deregulation of cellular energetics, the activation of invasion and metastasis, and genome instability. The identified miRNA-gene interactions offer valuable insights for developing targeted therapies for CLL. In addition, we underscored the importance of a practical and robust computational pipeline to ensure the reliability and reproducibility of miRNA sequencing data analysis.

References

Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y . Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020; 9:14. PMC: 7304189. DOI: 10.1186/s40164-020-00170-6. View

Kajuter H, Wellmann I, Khil L, Jockel K, Zhang C, Fink A . Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer J. 2021; 11(10):174. PMC: 8556420. DOI: 10.1038/s41408-021-00556-7. View

Pulte D, Castro F, Jansen L, Luttmann S, Holleczek B, Nennecke A . Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. J Hematol Oncol. 2016; 9:28. PMC: 4802710. DOI: 10.1186/s13045-016-0257-2. View

Trakala M, Arias C, Garcia M, Moreno-Ortiz M, Tsilingiri K, Fernandez P . Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur J Immunol. 2009; 39(3):810-9. DOI: 10.1002/eji.200838676. View

Condoluci A, Rossi D . Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment. Expert Rev Hematol. 2019; 12(2):89-98. DOI: 10.1080/17474086.2019.1575130. View

Amin N, Malek S . Gene mutations in chronic lymphocytic leukemia. Semin Oncol. 2016; 43(2):215-21. DOI: 10.1053/j.seminoncol.2016.02.002. View

Fakhri B, Danilov A . SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2023; 23(4):232-237. DOI: 10.1016/j.clml.2023.01.009. View

Patel K, Pagel J . Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021; 14(1):69. PMC: 8074228. DOI: 10.1186/s13045-021-01054-w. View

Shang R, Lee S, Senavirathne G, Lai E . microRNAs in action: biogenesis, function and regulation. Nat Rev Genet. 2023; 24(12):816-833. PMC: 11087887. DOI: 10.1038/s41576-023-00611-y. View

10.

Billi M, De Marinis E, Gentile M, Nervi C, Grignani F . Nuclear miRNAs: Gene Regulation Activities. Int J Mol Sci. 2024; 25(11). PMC: 11172810. DOI: 10.3390/ijms25116066. View

11.

Diener C, Keller A, Meese E . Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet. 2022; 38(6):613-626. DOI: 10.1016/j.tig.2022.02.006. View

12.

Lai X, Eberhardt M, Schmitz U, Vera J . Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic Acids Res. 2019; 47(15):7753-7766. PMC: 6735922. DOI: 10.1093/nar/gkz638. View

13.

Lai X, Schmitz U, Vera J . The Role of MicroRNAs in Cancer Biology and Therapy from a Systems Biology Perspective. Adv Exp Med Biol. 2022; 1385:1-22. DOI: 10.1007/978-3-031-08356-3_1. View

14.

Lai X, Bhattacharya A, Schmitz U, Kunz M, Vera J, Wolkenhauer O . A systems' biology approach to study microRNA-mediated gene regulatory networks. Biomed Res Int. 2013; 2013:703849. PMC: 3848080. DOI: 10.1155/2013/703849. View

15.

Balatti V, Croce C . Small Non-Coding RNAs in Leukemia. Cancers (Basel). 2022; 14(3). PMC: 8833386. DOI: 10.3390/cancers14030509. View

16.

Doghish A, Abulsoud A, Elshaer S, Abdelmaksoud N, Zaki M, El-Mahdy H . miRNAs as cornerstones in chronic lymphocytic leukemia pathogenesis and therapeutic resistance- An emphasis on the interaction of signaling pathways. Pathol Res Pract. 2023; 243:154363. DOI: 10.1016/j.prp.2023.154363. View

17.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

18.

Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A . Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009; 114(13):2589-97. DOI: 10.1182/blood-2009-05-224071. View

19.

Visone R, Rassenti L, Veronese A, Taccioli C, Costinean S, Aguda B . Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 2009; 114(18):3872-9. PMC: 2773482. DOI: 10.1182/blood-2009-06-229211. View

20.

Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W . Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015; 126(9):1106-17. PMC: 4560344. DOI: 10.1182/blood-2014-12-618025. View